Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지

Evaluation of NMP22 Measurement and $SurePath^{TM}$ Liquid-Based Cytology for the Diagnosis of Bladder Cancer and Comparison with Findings on Atypical Urothelial Cast in Voided Urine Sediments

  • Lee, June-Taek (Department of Biomedical Laboratory Science, Graduate School of Health Sciences, Eulji University) ;
  • Lee, Ji-Sook (Department of Biology, College of Natural Sciences, Daejeon University) ;
  • Kim, In-Sik (Department of Biomedical Laboratory Science, Graduate School of Health Sciences, Eulji University)
  • Published : 2009.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Urinary bladder cancer is diagnosed through urine cytology and cytoscopy with biopsy. An atypical urothelial cast is often found by voided urine cytology in a papillary urothelial cell carcinoma. The objective of this study is to demonstrate the significance of the evaluation of urinary nuclear matrix protein (NMP22) level and Sure Path Liquid-based cytology (SP-LBC) as compared to the examination of atypical urothelial cast in voided urine sediment for monitoring bladder cancer. From October 2007 to January 2008, we observed 3240 patients who visited the emergency laboratory of urology of Soonchunhyang University, Cheonan Hospital. Both NMP22 measurement and SP-LBC were performed in 31 patients who were positive in an atypical urothelial cast test. In particular, 26 men and 5 women were found to be atypical urothelial cast-positive persons. The average age for both men and women is 61.8. NMP22 test is positive in 23 of 31 cases (74.2%) from patients with atypical urothelial cast, while the test is negative in 8 of 31 cases (25.8%). The percentages of negativity, atypicality, suspicious malignancy, and malignancy in SP-LBC are 25.8% (8/31), 58.1% (18/31), 9.7% (3/31), and 6.5% (2/31), respectively. The relation of NMP22 positivity with the malignant degree in LBC is significant (P<0.01). Two malignant patients resulting from SP-LBC show the same results in histological examination. Overall, the study suggests the usefulness of NMP22 measurement and LBC as well as the examination of atypical urothelial cast for the diagnosis of early bladder cancer.

Keywords

References

  1. Badalament RA, Hermansen DK, Kimmel M, Herr HW, Fair WR, Whitmore WE. The sensitivity of bladder wash flow cytometory, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer. 1987. 60(7): 1423 -1427. https://doi.org/10.1002/1097-0142(19871001)60:7<1423::AID-CNCR2820600702>3.0.CO;2-6
  2. Kim HY, Chang SG, Kim JI. Significance of Urinary NMP22 patients with Bladder Tumor as a diagnostic test. Korean J Urol. 1998. 39: 5-10.
  3. Kim JS, Lee HM, Lee KH. Significance of nuclear matrix protein (NMP) in urine as a marker of for bladder transitional cell carcinoma. Korean J Urol 1999. 38: 259-262.
  4. Kim YH, Cho WJ, Hong KS, Shim BS, Kwon SW. Evaluation of the usefulness of immediate-cytospin wright-stained urine cytology in the screening and monitoring of bladder cancer. Korean J Lab Med 2003. 23: 164-169.
  5. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 bladder check test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Onco. 2006. 36: 172-175. https://doi.org/10.1093/jjco/hyi244
  6. Kwon DH, Hong SJ. The clinical utility of BTA TRAK, BTA stat, NMP22 and urine cytology in the diagnosis of bladder cancer; a comparative study. Korean J Urol 2003. 44: 721-726.
  7. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998. 52: 398 -402. https://doi.org/10.1016/S0090-4295(98)00219-2
  8. Lee KH. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer. Yonsei Medical Journal. 2001. 42(1): 14-18. https://doi.org/10.3349/ymj.2001.42.1.14
  9. Lee SY, Kang ES, Hong KS, Shim BS, Kim WK. Urinary NMP22 and BTA tests as screening markers for bladder transitional cell carcinoma. Korean J Clin Pathol. 2000. 20: 372-378.
  10. Moonen PM, Kiemeney LA, witjes JA. Urinary NMP22 bladder check test in the diagnosis of superficial bladder cancer. EurUro. 2005. 48: 951-956
  11. Ozer G, Altinel M, Kocak B, Yazicioglu A, Gonenc F. Value of urinary NMP-22 in patients with renal cell carcinoma. Urology. 2002. 60: 593-597. https://doi.org/10.1016/S0090-4295(02)01857-5
  12. Quek ML, Sanderson K, Daneshmand S, Stein JP. New molecular markers for bladder cancer detection. Curr Opin Urol. 2004. 14: 259-264. https://doi.org/10.1097/00042307-200409000-00003
  13. Reynolds T. Prevention study turns spotlight on bladder cancer. J Natl Cancer Inst. 1999. 91: 1102-1103. https://doi.org/10.1093/jnci/91.13.1102
  14. Seo SY, Cho SE, Hong KS, Shim BS, Kwon SW. Usefulness of NMP22 bladder check for the dianosis and monitoring of bladder cancer. Korean J Lab Med. 2007: 27: 22-27. https://doi.org/10.3343/kjlm.2007.27.1.22
  15. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion ceiteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999. 162: 53-57. https://doi.org/10.1097/00005392-199907000-00014
  16. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL. Use of a new tumor marker. Urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996. 156: 363-367. https://doi.org/10.1016/S0022-5347(01)65851-8
  17. Zippe C, Pandranfi L, Agarwal A. NMP22 is a sensitive, costeffective test in patients at risk for bladder cancer. J Urol. 1999. 161: 62-65. https://doi.org/10.1016/S0022-5347(01)62063-9